The Minister of Health and Care Services, Bent Høie, held an inspiring opening speech at the launch of Nordic Proof last week. Managing Director of Nordic Innovation, Svein Berg, says the emphasis and importance of Nordic cooperation to solve future challenges was put forward very clearly by the minister.
What happens when absolutely anyone can edit DNA? Can a new generation of brain scanners optimize our brain? Could an examination of Chopin’s (above) pickled heart solve the mystery of his early detah? This and much more in the week’s top reads from the frontier of health journalism, handpicked by the editors of The Health Brief.
The FDA has approved the first digital pill that can tell doctors when – and if – patients take their medicine, provoking praise as well as some dire “Big Brother” predictions.
Why does cancer immunotherapy work for some patients, but not others? The answer may lie in your gut.
Ably Medical recently had a visit from Tordis Abrahamsen (90) to hear about her ideas for of the Ably bed design.
Fortuna announces today the closing of its USD 25 million Series B financing. The proceeds will enable the company to conduct Phase I/IIa clinical trials in Parkinson’s Disease and Spinal Cord Injury. Amgen Ventures and other new investors join existing shareholders, including Salamander Invest to support the development of Fortuna’s lead programs and its neuro-regenerative technology platforms. In addition to clinical development, the financing will enable further expansion of Fortuna’s automated robotic manufacturing capabilities.
The Centre for Connected Care (C3) aims to succeed in accelerating adoption and diffusion of patient-centric innovations, i.e. innovations that change patient pathways and delivery systems and increases growth in the healthcare industry. The themes are patient-centric healthcare delivery, innovative infrastructure and interoperability and commercialization, diffusion and adoption
Angel Challenge Health is a workshop based program for Startup Investors and Health Startups. During 8 evening sessions, 20 angel investors work closely together analyzing 20 investor-ready startups that are competing for an investment of 1 million NOK, whilst learning the mechanics and possibilities of investing in the health sector.
INNOLABS aims at fostering collaboration, transfer of knowledge and opportunities among SMEs from different countries and sectors to develop, improve and deliver disruptive technologies on mHealth, personalized healthcare and ageing populations.